# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Scotiabank analyst Sung Ji Nam initiates coverage on Myriad Genetics (NASDAQ:MYGN) with a Sector Outperform rating and annou...
Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the addition of a new ...
Jefferies analyst Tycho Peterson assumes Myriad Genetics (NASDAQ:MYGN) with a Underperform rating and lowers Price Target of...
Myriad's Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiat...